Association of secondary prevention medication use after myocardial infarction with mortality in hemodialysis patients.

ABSTRACT:

Background

Mortality after myocardial infarction (MI) among patients undergoing dialysis is high. However, studies investigating the use of secondary prevention medications after MI and clinical outcomes in dialysis patients are lacking. This study aimed to examine the association of the number of guideline-recommended medications (antiplatelets, β-blockers, statins and renin-angiotensin-aldosterone system inhibitors) with all-cause mortality after MI in hemodialysis (HD) patients.

Methods

We conducted a nationwide cohort study of incident HD patients who were admitted for MI between 1 January 2010 and 31 December 2014 and were followed up until 31 December 2015, using Taiwan's national health insurance research database.

Results

Of 1471 patients (mean age 68 years, 4

SUBMITTER: Lin TY 

PROVIDER: S-EPMC9613425 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature